Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001564590-21-060882
Filing Date
2021-12-21
Accepted
2021-12-21 17:04:18
Documents
11

Document Format Files

Seq Description Document Type Size
1 S-3 achv-s3.htm S-3 877746
2 EX-1.2 achv-ex12_153.htm EX-1.2 273478
3 EX-4.12 achv-ex412_131.htm EX-4.12 69865
4 EX-4.13 achv-ex413_132.htm EX-4.13 531473
5 EX-5.1 achv-ex51_152.htm EX-5.1 46509
6 EX-23.2 achv-ex232_102.htm EX-23.2 2379
7 GRAPHIC g5tzfhncri05000003.jpg GRAPHIC 5573
8 GRAPHIC g5tzfhncri05000004.jpg GRAPHIC 5573
9 GRAPHIC g5tzfhncri05000002.jpg GRAPHIC 5573
10 GRAPHIC g5tzfhncri05000001.jpg GRAPHIC 5573
11 GRAPHIC gq4ucempbrpe000001.jpg GRAPHIC 11818
  Complete submission text file 0001564590-21-060882.txt   1850404
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-261811 | Film No.: 211510099
SIC: 2835 In Vitro & In Vivo Diagnostic Substances